Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q2 2021 · 10-Q
Revenue$23.79M$23.79M−83.3% vs Q2 2020 Net Income-$11.62M-$11.62MN/M vs Q2 2020 EPS Diluted-$0.40-$0.40N/M vs Q2 2020 Gross Profit$10,774,000−30.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,230,000N/M Free Cash Flowderived-$1,554,000N/M Margins · derivedGross margin45.3%+34.4 pt vs Q2 2020
Operating margin5.8%+10.0 pt vs Q2 2020
Net margin-48.9%−44.1 pt vs Q2 2020
ended Nov 29, 2020 · filed Jan 7, 2021 · 39 d after period end